Unicycive Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with the three months ended March 31, 2023. Unicycive is a development-stage biotechnology company focused on Oxylanthanum Carbonate for hyperphosphatemia in chronic kidney disease and UNI 494 for acute kidney injury. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Licensing revenue | $0 | $675,000 |
| Research and development expense | $6.813 million | $3.030 million; up 125% |
| General and administrative expense | $2.391 million | $1.847 million; up 29% |
| Operating loss | $9.204 million | $4.202 million |
| Net loss | $20.963 million | $14.575 million |
| Net loss attributable to common stockholders | $21.171 million | $14.767 million |
| Basic and diluted loss per share | $0.61 | $0.97 |
| Cash used in operating activities | $6.456 million | $3.920 million |
Revenue was nil in Q1 2024, so a revenue-based margin is not meaningful. The reported loss included an $11.808 million expense from remeasuring the warrant liability, compared with $10.375 million in Q1 2023; this is a fair-value accounting charge, not operating cash outflow.
Cash and cash equivalents were $48.930 million at March 31, 2024, versus $9.701 million at December 31, 2023. Financing activities provided $45.691 million, primarily from the March private placement; investing activities used $6,000. Current assets were $51.676 million and current liabilities $30.282 million, including a $24.941 million warrant liability. The company reported $715,000 of operating lease liabilities; the filing does not report conventional outstanding borrowings at period-end.
Management stated that current resources are sufficient to continue operations for at least one year after the financial statements became available to issue, while also expecting to need additional capital. Accumulated deficit was $85.504 million. No numerical revenue, earnings, or cash-flow guidance was provided.
Material changes and financing
- R&D expense rose $3.783 million, primarily due to a $3.6 million increase in drug development costs. G&A increased $544,000, including higher stock compensation, labor, travel, rent, and other costs.
- On March 13, 2024, the company issued 50,000 shares of Series B-1 Convertible Preferred Stock for $50 million gross proceeds and received $46.2 million net of issuance costs. The shares have an initial $1.00 conversion price, subject to adjustment, and require stockholder approval for conversion beyond the applicable 19.9% cap.
- Series B-1 accrues dividends at 8% annually, compounded; the rate increases to 14% if stockholder approval is not obtained at the first meeting after issuance. The company recorded $208,000 of preferred dividends payable in Q1.
- The company exchanged Series A-2 preferred shares for Series A-2 Prime shares and amended related preferred-stock warrants. Common shares outstanding increased from 34.756 million at December 31, 2023 to 37.607 million at March 31, 2024. Further conversion or warrant exercise could result in substantial dilution.
- Q1 2023 licensing revenue of $675,000 related to the Lotus agreement; no licensing revenue was recognized in Q1 2024. Potential milestones and royalties under licensing arrangements were excluded from transaction price because achievement or sales remained uncertain.
Outlook, risks, and unusual items
- Management expects operating losses and cash outflows to continue, with R&D expense expected to increase as programs advance and the company pursues regulatory approval and potential commercialization. G&A is also expected to rise with staffing, public-company compliance, and related costs.
- The company says it will require additional capital to fund clinical trials, product development, and commercialization. Financing may not be available on acceptable terms or at all; a shortfall could force delays, reductions, or termination of programs, or licensing of product rights.
- Key risks include clinical and regulatory outcomes, FDA approval and market acceptance, manufacturing and supply readiness, intellectual-property matters, access to financing, and reliance on employees and third-party service providers. The filing reports no material change to risk factors from the 2023 Form 10-K and no pending material legal proceedings.
- The $24.941 million warrant liability is measured using Level 3 unobservable inputs, including assumptions about FDA approval, technical milestones, stock price, volatility, and warrant term. Changes in these estimates can materially affect reported earnings.
- Management concluded that disclosure controls and internal control over financial reporting were not effective at March 31, 2024 because of a material weakness involving insufficient accounting staffing and expertise, inadequate formal procedures, and gaps in review and segregation of duties. Remediation includes added accounting personnel and third-party support; completion is expected by year-end 2024, with additional costs expected.
Investor verification priorities
- Track cash burn, development spending, and the timing and terms of any additional financing against management’s stated minimum one-year liquidity outlook.
- Verify the status and requirements of the Series B stockholder-approval vote, dividend accruals, conversion terms, and resulting potential dilution.
- Monitor Oxylanthanum Carbonate’s regulatory and commercial-readiness milestones, and UNI 494’s development progress; the filing provides no specific near-term milestone dates.
- Assess the warrant liability’s Level 3 valuation assumptions and its impact on reported net loss versus cash use.
- Follow remediation of the material weakness and confirm whether disclosure controls and financial-reporting controls become effective.